Company
Headquarters: Taipei City, Taiwan
TW$5.26 Billion
TWD as of July 1, 2025
US$179.7 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $233.33 B |
| Boston Scientific Corporation | $154.34 B |
| Stryker | $151.06 B |
| Medtronic | $113.25 B |
| Edwards Lifesciences Corporation | $45.05 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Brighten Optix Corporation researches and develops, manufactures, and sells specialty contact lenses in Taiwan and the Asia Pacific region. The company offers its products under the Ortho-K myopia management lens, HiClear gas permeable (GP) lens, Briomoist lens care systems, SynergEyes hybrid lens, and Large Diameter GP lens. It also provides OEM/ODM collaboration services. The company is based in Taipei City, Taiwan.
Brighten Optix Corp has the following listings and related stock indices.
Stock: TWSE: 6747 wb_incandescent